Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 1.00 |
| ▸ | SHBG | P04278 | 6/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.78 |
| ▸ | TSHR | P16473 | 4/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | PGR | P06401 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxyprogesterone SCHEMBL8068 | 1.00 | LMNA (1.00) | LMNASHBGCYP2C19SERPINA6SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL30657985 | 1.00 | LMNA (1.00) | LMNASHBGCYP2C19SERPINA6SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL18261234 | 1.00 | LMNA (1.00) | LMNASHBGCYP2C19SERPINA6SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL23456341 | 1.00 | LMNA (1.00) | LMNASHBGCYP2C19SERPINA6SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL13558389 | 1.00 | LMNA (1.00) | LMNASHBGCYP2C19SERPINA6SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL24287585 | 1.00 | LMNA (1.00) | LMNASHBGCYP2C19SERPINA6SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL3931615 | 1.00 | LMNA (1.00) | LMNASHBGCYP2C19SERPINA6SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL14523053 | 1.00 | LMNA (1.00) | LMNASHBGCYP2C19SERPINA6SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL14546356 | 1.00 | LMNA (1.00) | LMNASHBGCYP2C19SERPINA6SMN1; SMN2 | |
| Hydroxyprogesterone SCHEMBL27048177 | 1.00 | LMNA (1.00) | LMNASHBGCYP2C19SERPINA6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030027772-A1 | Composition containing at least one inhibitor of the enzyme 3-beta-HSD | L'OREAL (FR) | 2003-02-06 | — | — | US | claimed |
| EP-1269984-A1 | Cosmetic and/or dermatological andor pharmaceutical composition for topical application containing at least one compound inhibiting 3-beta-HSD enzyme | L'OREAL (FR) | 2003-01-02 | — | — | EP | claimed |
| US-5989568-A | TREATING WRINKLES AND FINE LINES | L'OREAL (FR) | 1999-11-23 | — | — | US | claimed |
| US-5900242-A | TOPICALLY APPLYING DEHYDRO-EPI-ANDROSTERONE SULFATE MIXTURE TO REVIVE RADIANCE OF HUMAN SKIN | SOCIETE L'OREAL S.A. (FR) | 1999-05-04 | — | — | US | claimed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | claimed |
| US-4885289-A | APPLYING ANTIANDROGEN TO SKIN | GILLETTE COMPANY | 1989-12-05 | — | — | US | claimed |
| US-20230146925-A1 | DEPOT FORMULATIONS | DURECT CORPORATION (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220280646-A1 | COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT AND HIGH VISCOSITY LIQUID CARRIER MATERIAL | DURECT CORPORATION (US) | 2022-09-08 | — | — | US | disclosed |
| US-11202762-B2 | Drug delivery system for delivery of acid sensitivity drugs | DSM IP ASSETS B.V. (NL) | 2021-12-21 | — | — | US | disclosed |
| EP-2441456-B1 | DHEA compositions for treating menopause | ENDORECHERCHE INC (CA) | 2021-10-06 | — | — | EP | disclosed |
| US-20210121467-A1 | DEPOT FORMULATIONS | DURECT CORPORATION (US) | 2021-04-29 | — | — | US | disclosed |
| US-20210069169-A1 | PHARMACEUTICAL COMPOSITIONS | ENDORECHERCHE, INC. (CA) | 2021-03-11 | — | — | US | disclosed |
| US-20210052509-A1 | DRUG DELIVERY SYSTEM FOR DELIVERY OF ACID SENSITIVITY DRUGS | DSM IP ASSETS BV (NL) | 2021-02-25 | — | — | US | disclosed |
| EP-1006935-A1 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM | Southern Biosystems, Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| US-5989568-A | TREATING WRINKLES AND FINE LINES | L'OREAL (FR) | 1999-11-23 | — | — | US | disclosed |
| US-5900242-A | TOPICALLY APPLYING DEHYDRO-EPI-ANDROSTERONE SULFATE MIXTURE TO REVIVE RADIANCE OF HUMAN SKIN | SOCIETE L'OREAL S.A. (FR) | 1999-05-04 | — | — | US | disclosed |
| WO-1999013913-A2 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM AS A DEVICE | SOUTHERN BIOSYSTEMS, INC. (US) | 1999-03-25 | — | — | WO | disclosed |
| US-5747058-A | ACTIVE MATERIALS AND CARRIERS FOR CONTROLLED RELEASE SUBSTANCE | SOUTHERN BIOSYSTEMS, INC. (US) | 1998-05-05 | — | — | US | disclosed |
| WO-1996039995-A1 | HIGH VISCOSITY LIQUID CONTROLLED DELIVERY SYSTEM | SOUTHERN BIOSYSTEMS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-4286587-A | Vaginal drug delivery system made from polymer | ALZA CORPORATION (US) | 1981-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11202762-B2 | Drug delivery system for delivery of acid sensitivity drugs | IDUA, PEPD, ALAD | LMNA 2086/4885SHBG 3222/4885CYP2C19 650/4885 |
| US-20220280646-A1 | COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT AND HIGH VISCOSITY LIQUID CARRIER MATERIAL | HACD3, ACADM, LDHB | LMNA 1958/4885SHBG 1353/4885CYP2C19 1536/4885 |
| US-20210069169-A1 | PHARMACEUTICAL COMPOSITIONS | SHBG, CYP19A1, HSD17B11 | LMNA 238/4885SHBG 1/4885CYP2C19 1004/4885 |
| US-20210052509-A1 | DRUG DELIVERY SYSTEM FOR DELIVERY OF ACID SENSITIVITY DRUGS | IDUA, PEPD, ALAD | LMNA 2086/4885SHBG 3222/4885CYP2C19 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.